Multidisciplinary Consortium Sets Sights on Developing AI to Detect Gliomas

A new multidisciplinary consortium is combining knowledge from several different disciplines to develop new methods for diagnosing and treating gliomas. Comprised of Sweden’s Umeå University and Umeå University Hospital and PSE Data Security from Switzerland, the consortium will amalgamate knowledge on data security, brain tumors and machine learning to potentially create new and more effective diagnostic and treatment techniques for the brain tumor.

Glioma is a relatively common type of brain tumor that occurs in roughly 33% of brain tumor patients and affects around 19,000 new patients in the United States every year.

Members of the consortium signed a collaboration agreement in a Stockholm meeting last December. They will use anomaly detection models that are effective at combing through massive datasets to help improve early glioma detection. Detecting gliomas in the early stages significantly increases rates of treatment success, but early-stage gliomas can be quite difficult to diagnose.

Heights AI partner Wilfred de Graaf noted that anomaly detection models have been successful at dealing with issues such as detecting money laundering in the financial sector. The anomaly detection works by identifying data points, events or entities that are outside of the normal or expected range and deviate from the standard.

Healthcare provider Region Västerbotten and Umeå University have collected a massive data set of health samples and data from 140,000 patients over the past three decades, which will be critical to the collaboration. Since artificial intelligence (AI) models work more effectively when they have large and high-quality data sets to learn from, this data set will be integral to helping the research team develop novel diagnostic and treatment techniques for gliomas.

Traditional methods of statistical analyses have consistently failed to deliver notable improvements in early glioma detection due to the lack of sufficient data points with predictive value. Many experts in the field colloquially refer to glioma detection as looking for a needle in the haystack thanks to the complexity involved. However, with the advent and proliferation of AI and machine-learning technology over the past decades, researchers are increasingly leveraging the technology to improve healthcare services.

Both PSA Data Security and Heights AI are experts in the nascent artificial intelligence field and have developed AI models that can essentially spot the needle in the haystack much more effectively than previous methods ever could. Umeå University professor of oncology Beatrice Melin notes that the university has a history of translating innovations into clinical applications and said she is happy to be part of a collaboration that will help accelerate the development of new brain tumor detection measures.

When the early detection or diagnosis of gliomas becomes possible, the drugs being developed by entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) could have a heightened chance of delivering desirable clinical outcomes for affected patients.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN